NEW YORK (GenomeWeb) – PredictImmune announced today that it has entered a commercial agreement with Addenbrooke's Hospital — part of Cambridge University Hospitals National Health Service Foundation Trust — to provide the company's PredictSure IBD prognostic assay to clinicians and gastroenterologists in the UK and Ireland.
As part of the agreement, the hospital's East Midlands and East of England Genomic Laboratory hub will manage and facilitate fulfillment of PredictSure IBD orders, in addition to receiving and processing all samples.
PredictImmune's CE-IVD PredictSure platform integrates a blood-based biomarker assay and a proprietary algorithm to identify biomarkers linked to irritable bowel disease (IBD), including Crohn's disease and ulcerative colitis.
PredictImmune said that the agreement will help both clinicians and patients understand the likely course of disease and makes available more treatment choices from initial diagnosis.
"Partnering with Addenbrooke's to make PredictSure available across the UK and Ireland feels very appropriate, given the long-term nature of our collaboration to date," PredictImmune CEO Paul Kinnon said in a statement. "We are excited to see PredictSure IBD become available to UK and Irish patients, particularly because we understand the life-changing benefits that early and accurate prediction of the likely course of their IBD diseases can have on their quality of life."
Financial details of the agreement were not disclosed.
PredictImmune previously announced in March the entry of PredictSure IBD into NICE's Diagnostic Assessment Programme, which evaluates new diagnostic technologies for the UK's NHS.